English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cyclosporin is a difficult drug to use; however, we are delighted to have it. Without any doubt, cyclosporin has dramatically improved long-term graft survival in renal transplant patients and opened the possibility of successful transplantation of vital organs such as the heart and the liver. Nevertheless, despite major advances there are significant drawbacks, and a number of practical problems persist. For instance, 10 years after renal transplantation roughly one-half of the patients have lost their grafts, either as a result of acute rejection episodes or as a result of what is called 'chronic rejection' but might perhaps be better designated 'chronic graft failure'. With this in mind, a debate continues on key issues such as: 'What is the ideal dose?', 'What is the best way to monitor this drug?', 'Are measurements of trough levels adequate?' and with regard to overimmunosuppression with the inherent risk of nephrotoxicity 'What is the magnitude of the risk?'.

Cyclosporin as microemulsion—is it a new drug?